M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.
Chiara Cerrato,Maria Teresa Petrucci,Renato Zambello,Barbara Gamberi,Stelvio Ballanti,Paola Omedè,Salvatore Palmieri,Rossella Troia,Stefano Spada,Alessandro Gozzetti,Tommaso Caravita,Antonio Spadano,Antonio Palumbo,Vittorio Montefusco,Pellegrino Musto,Michele Cavo,Mario Boccadoro +16 more
TL;DR: High and comparable rates of MRD negativity were seen in NDMM pts after 4 28-day induction cycles with KRd followed by ASCT and 4 KRd consolidation and after 12 KRd c...
Journal ArticleDOI
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Fortunato Morabito,Massimo Gentile,Stefania Ciolli,Maria Teresa Petrucci,Sara Galimberti,Giuseppe Mele,Antonio Francesco Casulli,Donato Mannina,Eugenio Piro,Graziella Pinotti,Salvatore Palmieri,Lucio Catalano,Vincenzo Callea,Massimo Offidani,Pellegrino Musto,Sara Bringhen,Luca Baldini,Patrizia Tosi,Francesco Di Raimondo,Mario Boccadoro,Antonio Palumbo,Michele Cavo +21 more
TL;DR: In this article, the safety and efficacy of bortezomib-based therapy in multiple myeloma patients with renal impairment was investigated and the 2-yr estimate of response duration and overall survival was 70% and 51%, respectively.
Journal ArticleDOI
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: Updated results
Valeria Magarotto,Claudia Crippa,Norbert Pescosta,Tommasina Guglielmelli,Federica Cavallo,Sara Pezzatti,Samantha Ferrari,Anna Marina Liberati,Stefania Oliva,Francesca Patriarca,Massimo Offidani,Paola Omedè,Vittorio Montefusco,Maria Teresa Petrucci,Nicola Giuliani,Roberto Passera,Giuseppe Pietrantuono,Mario Boccadoro,Paolo Corradini,Antonio Palumbo +19 more
TL;DR: Bortezomib-induction followed by ASCT and lenalidomide consolidation-maintenance is a valuable option for elderly myeloma patients, with the greatest benefit in those younger than 70 years of age.
Journal ArticleDOI
VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study
A. Levis,Anselmo Ap,Achille Ambrosetti,F. Adamo,Marilena Bertini,Elena Cavalieri,Paolo Gavarotti,Angelo Genua,Marina Liberati,Vincenzo Pavone,Daniela Pietrasanta,M. M. Ricetti,Delia Rota Scalabrini,Flavia Salvi,Umberto Vitolo,Emanuele Angelucci,Mario Boccadoro,Eugenio Gallo,Franco Mandelli +18 more
TL;DR: VEPEMB is an effective and low toxic regimen for HL in the elderly and co-morbidity is a prognostic factor more important than age itself.
Journal ArticleDOI
Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status.
Umberto Dianzani,Alessandro Pileri,Mario Boccadoro,Antonio Palumbo,P. Pioppo,Alberto Bianchi,A Camponi,Giorgio Fossati,Silvano Battaglio,Massimo Massaia +9 more
TL;DR: The phenotypic pattern of peripheral blood T (PBT) lymphocytes was correlated with diagnosis and clinical status in 63 patients with monoclonal gammopathies (MGs) and the number of activated suppressor/cytotoxic cells was closely correlated with diagnoses and disease status.